The Truth and Consequences of the COURAGE Trial

The Truth and Consequences of the COURAGE Trial Dean J. Kereiakes, Paul S. Teirstein, Ian J. Sarembock, David R. Holmes, Jr, Mitchell W. Krucoff, William W. O’Neill, Ron Waksman, David O. Williams, Jeffrey J. Popma, Maurice Buchbinder, Roxana Mehran, Ian T. Meredith, Jeffrey W. Moses, Gregg W. Stone...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2007-10, Vol.50 (16), p.1598-1603
Hauptverfasser:	Kereiakes, Dean J., MD, FACC, Teirstein, Paul S., MD, FACC, Sarembock, Ian J., MB, ChB, MD, Holmes, David R., MD, Krucoff, Mitchell W., MD, FACC, O’Neill, William W., MD, Waksman, Ron, MD, FACC, Williams, David O., MD, Popma, Jeffrey J., MD, FACC, Buchbinder, Maurice, MD, FACC, Mehran, Roxana, MD, Meredith, Ian T., MBBS, PhD, FACC, Moses, Jeffrey W., MD, FACC, Stone, Gregg W., MD, FACC
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - therapeutic use Angina pectoris Angina, Unstable - therapy Angioplasty Angioplasty, Balloon, Coronary Aspirin - therapeutic use Cardiology Cardiovascular Cardiovascular disease Coronary Angiography Coronary Stenosis - therapy Coronary vessels Heart attacks Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Internal Medicine Myocardial Ischemia - therapy Patient Compliance Platelet Aggregation Inhibitors - therapeutic use Randomized Controlled Trials as Topic Retreatment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The Truth and Consequences of the COURAGE Trial Dean J. Kereiakes, Paul S. Teirstein, Ian J. Sarembock, David R. Holmes, Jr, Mitchell W. Krucoff, William W. O’Neill, Ron Waksman, David O. Williams, Jeffrey J. Popma, Maurice Buchbinder, Roxana Mehran, Ian T. Meredith, Jeffrey W. Moses, Gregg W. Stone Percutaneous coronary intervention (PCI) has played an integral role in the therapeutic management strategies for patients who present with either acute coronary syndromes or stable angina pectoris. The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial enrolled patients with chronic stable angina and at least 1 significant (≥70%) angiographic coronary stenosis who were randomly assigned to an initial treatment of either PCI in conjunction with optimal medical therapy or optimal medical therapy alone. Although the initial management strategy of PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events, improvement in angina-free status and a reduction in the requirement for subsequent revascularization was observed. An in-depth analysis of the COURAGE trial design and execution is provided.
ISSN:	0735-1097 1558-3597
DOI:	10.1016/j.jacc.2007.07.063